CN107406511A - Pcsk9抗体、其抗原结合片段及其医药用途 - Google Patents

Pcsk9抗体、其抗原结合片段及其医药用途 Download PDF

Info

Publication number
CN107406511A
CN107406511A CN201680013073.1A CN201680013073A CN107406511A CN 107406511 A CN107406511 A CN 107406511A CN 201680013073 A CN201680013073 A CN 201680013073A CN 107406511 A CN107406511 A CN 107406511A
Authority
CN
China
Prior art keywords
seq
chain variable
variable region
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680013073.1A
Other languages
English (en)
Other versions
CN107406511B (zh
Inventor
屈向东
叶鑫
徐韶瑜
袁蓓
崔东冰
胡齐悦
张蕾
许志宾
陶维康
张连山
孙飘扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Jiangsu Hengrui Medicine Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN107406511A publication Critical patent/CN107406511A/zh
Application granted granted Critical
Publication of CN107406511B publication Critical patent/CN107406511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供一种PCSK9抗体、其抗原结合片段及其医药用途。提供包含所述PCSK9抗体CDR区的嵌合抗体、人源化抗体以及包含PCSK9抗体及其抗原结合片段的药物组合物，以及其作为降血脂药物的用途。特别地，涉及一种人源化的PCSK9抗体在制备用于治疗PCSK9介导的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201680013073.1A 2015-12-31 2016-12-20 Pcsk9抗体、其抗原结合片段及其医药用途 Active CN107406511B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015110246182 2015-12-31
CN201511024618 2015-12-31
PCT/CN2016/111053 WO2017114230A1 (zh) 2015-12-31 2016-12-20 Pcsk9抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
CN107406511A true CN107406511A (zh) 2017-11-28
CN107406511B CN107406511B (zh) 2021-01-19

Family

ID=59224496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680013073.1A Active CN107406511B (zh) 2015-12-31 2016-12-20 Pcsk9抗体、其抗原结合片段及其医药用途

Country Status (12)

Country Link
US (1) US10793643B2 (zh)
JP (1) JP7032662B2 (zh)
KR (1) KR20180093068A (zh)
CN (1) CN107406511B (zh)
AU (1) AU2016382932B2 (zh)
BR (1) BR112018013256A2 (zh)
CA (1) CA3009904A1 (zh)
HK (1) HK1244828A1 (zh)
MX (1) MX2018007925A (zh)
RU (1) RU2739208C2 (zh)
TW (1) TWI735499B (zh)
WO (1) WO2017114230A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532491A (ja) * 2017-06-30 2020-11-12 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． Ｐｃｓｋ−９抗体を含む医薬組成物及びその使用
CN110981962B (zh) * 2019-12-19 2022-07-12 中国药科大学 Pcsk9抗体、其抗原结合片段及其应用
TW202144436A (zh) 2020-03-19 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 膽固醇相關疾病的治療方法
CN114369164A (zh) * 2020-10-15 2022-04-19 苏州君盟生物医药科技有限公司 抗pcsk9单克隆抗体的生产工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161808A1 (en) * 2006-06-30 2014-06-12 Bristol-Myers Squibb Company Antibodies that bind novel pcsk9 variants
WO2014150983A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
CN104583237A (zh) * 2012-05-08 2015-04-29 奥尔德生物控股有限责任公司 抗pcsk9抗体及其用途
CN105037554A (zh) * 2015-06-12 2015-11-11 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2567285A1 (en) * 2004-05-18 2005-11-24 Silverbrook Research Pty Ltd Method and apparatus for security document tracking
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US20140121123A1 (en) 2010-10-29 2014-05-01 Kevin Caili Wang Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
MA34818B1 (fr) 2010-12-22 2014-01-02 Genentech Inc Anticorps anti-pcsk9 et procédés d'utilisation
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
CN103562227B (zh) 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
EP2731623A1 (en) 2011-07-14 2014-05-21 Pfizer Inc Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
AR087715A1 (es) * 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2794661B1 (en) 2011-12-20 2019-03-06 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US20150140005A1 (en) 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
RU2015101113A (ru) * 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
CN105001336A (zh) * 2014-04-18 2015-10-28 上海复旦张江生物医药股份有限公司 Pcsk9拮抗剂
WO2015200438A1 (en) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161808A1 (en) * 2006-06-30 2014-06-12 Bristol-Myers Squibb Company Antibodies that bind novel pcsk9 variants
CN104583237A (zh) * 2012-05-08 2015-04-29 奥尔德生物控股有限责任公司 抗pcsk9抗体及其用途
WO2014150983A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
CN105037554A (zh) * 2015-06-12 2015-11-11 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途

Also Published As

Publication number Publication date
EP3398968A1 (en) 2018-11-07
US20190016825A1 (en) 2019-01-17
RU2739208C2 (ru) 2020-12-21
TW201725216A (zh) 2017-07-16
HK1244828A1 (zh) 2018-08-17
TWI735499B (zh) 2021-08-11
MX2018007925A (es) 2018-08-29
AU2016382932B2 (en) 2022-12-08
RU2018125003A (ru) 2020-02-03
EP3398968A4 (en) 2019-08-07
US10793643B2 (en) 2020-10-06
KR20180093068A (ko) 2018-08-20
CA3009904A1 (en) 2017-07-06
WO2017114230A1 (zh) 2017-07-06
CN107406511B (zh) 2021-01-19
JP2019509254A (ja) 2019-04-04
RU2018125003A3 (zh) 2020-05-13
JP7032662B2 (ja) 2022-03-09
AU2016382932A1 (en) 2018-07-19
BR112018013256A2 (zh) 2018-12-11

Similar Documents

Publication Publication Date Title
CN108779179B (zh) Cd47抗体、其抗原结合片段及其医药用途
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN108472349A (zh) Lag-3抗体、其抗原结合片段及其医药用途
CN105026428A (zh) PD-l抗体、其抗原结合片段及其医药用途
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN107406511A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
CN109983032A (zh) Tim-3抗体、其抗原结合片段及医药用途
CN106573053A (zh) 干扰素α和ω抗体拮抗剂
JP2018509894A (ja) Ｐｃｓｋ９抗体、及び医薬組成物とその使用
CN109963877A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
JP2023510787A (ja) 抗ａｎｇｐｔｌ３抗体及びその応用
CN107531797A (zh) 凝血酶抗体、其抗原结合片段及医药用途
CN108178798A (zh) pH工程化的NGF抗体及其医药用途
JP2022535810A (ja) 抗結合組織成長因子抗体およびその適用
CN107531795A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
CN106554420A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
EP3398968B1 (en) Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof
WO2013166011A2 (en) Binding proteins having tethered light chains
KR20240035835A (ko) 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용
AU2021223128A1 (en) Pharmaceutical composition containing anti-IL-4R antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244828

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220215

Address after: 215126 No. 350, Fengli street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: SUZHOU SUNCADIA BIOPHARMACEUTICALS Co.,Ltd.

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240123

Address after: No. 55 Kangyao South Road, Huangpu District, Guangzhou City, Guangdong Province, 510700

Patentee after: Guangdong Jiangsu Hengrui Medicine Co.,Ltd.

Country or region after: China

Patentee after: SUZHOU SUNCADIA BIOPHARMACEUTICALS Co.,Ltd.

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 215126 No. 350, Fengli street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee before: SUZHOU SUNCADIA BIOPHARMACEUTICALS Co.,Ltd.

Country or region before: China

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right